Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
BPMED CO., LTD. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and several distinct art units, indicating that the company's current patenting efforts cover different technical aspects of the biotechnology field. This distribution prevents the portfolio's progress from being entirely dependent on a single examiner. Engaging with various art units allows the company to protect its innovations across different specialized sections of the USPTO.
The busiest examiner, GOUGH, TIFFANY MAUREEN, is responsible for 1 pending office action. Given that there are 2 pending office actions in total, the workload is split among the examiners. This balanced approach allows the company to navigate the requirements of multiple art units while receiving feedback from different examiners. The remaining 1 pending office action is handled by another examiner, ensuring that the company's pharmaceutical-related intellectual property is not subject to the review of only a single individual.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOUGH, TIFFANY MAUREEN | 1 | 31.7% | +46.5% |
| IANNUZO, NATALIE NMN | 1 | 12.2% | +71.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18703591 | COMPOSITION FOR AMELIORATING HAIR LOSS COMPRISING BOTULINUM-DERIVED PEPTIDE | IANNUZO, NATALIE NMN | 72d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18703591 | COMPOSITION FOR AMELIORATING HAIR LOSS COMPRISING BOTULINUM-DERIVED PEPTIDE | IANNUZO, NATALIE NMN | 72d |
| 18704129 | COMPOSITION COMPRISING BOTULINUM-DERIVED PEPTIDE FOR PAIN RELIEF | GOUGH, TIFFANY MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704129 | COMPOSITION COMPRISING BOTULINUM-DERIVED PEPTIDE FOR PAIN RELIEF | GOUGH, TIFFANY MAUREEN | 1651 | §102 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18703591 | COMPOSITION FOR AMELIORATING HAIR LOSS COMPRISING BOTULINUM-DERIVED PEPTIDE | IANNUZO, NATALIE NMN | 1653 | §103 | Final Rejection | 72d | Pending | Apr 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBPMED CO., LTD. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Tiffany Maureen Gough has the most, with 1 of BPMED CO., LTD.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
